Preliminary mechanism of inhibitor of SGLT2 in fatty liver cold ischemia injury

Biochem Biophys Res Commun. 2023 Feb 26:646:96-102. doi: 10.1016/j.bbrc.2022.12.055. Epub 2022 Dec 29.

Abstract

With rapid development of liver transplantation technology, the demand for transplants have reached beyond the supply of organs, and thus development of effective strategies to reduce cold ischemia injury in fatty liver is important. Here, we explored the potential effect of SGLT-2 inhibitor in cold ischemia injury, fatty livers from 2 weeks methionine and choline deficient diet (MCD) rats were administered. After one week of intragastric administration of Sodium-dependent glucose transporters (SGLT-2) inhibitor empagliflozin (EMPA) or NaCI, liver were stored for 24 h. The results showed that EMPA could significantly reduce the cold ischemic injury in the mitochondria of fatty liver. To explore the mechanism, signal transducers and activators of transcription 3(STAT3) inhibitor AG490 group was used in a similar manner. We detected the changes in p-signal transducers and activators of transcription 3 (P-STAT3), alcohol-dehydrogenase 2 (ALDH2) and degree of apoptosis in three distinct groups. The results suggested that the protein expression of P-STAT3 and ALDH2 was higher in the EMPA group than in other two groups, whereas extent of apoptosis in the EMPA group was lower than other two groups. The data suggested that SGLT2 inhibitors could alleviate cold ischemia damage of mitochondria in fatty liver, which may be related to the inhibition of apoptosis and the activation of P-STAT3 and ALDH2.

Keywords: Apoptosis; Cold ischemia; Fatty liver; Mitochondria; Sodium-dependent glucose transporters (SGLT-2).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cold Ischemia*
  • Fatty Liver* / metabolism
  • Ischemia
  • Liver / metabolism
  • Rats
  • Sodium-Glucose Transporter 2

Substances

  • Sodium-Glucose Transporter 2